United States (US) PD-1 and PD-L1 Inhibitors Market (2025-2031) | Companies, Segmentation, Outlook, Industry, Size & Revenue, Growth, Forecast, Competitive Landscape, Value, Share, Analysis, Trends

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) PD-1 and PD-L1 Inhibitors Market - Industry Life Cycle

3.4 United States (US) PD-1 and PD-L1 Inhibitors Market - Porter's Five Forces

3.5 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Inhibitors, 2021 & 2031F

3.6 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Application, 2021 & 2031F

3.7 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer in the US population

4.2.2 Rising adoption of immunotherapy treatments

4.2.3 Growing investments in research and development of PD-1 and PD-L1 inhibitors

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for drug approval

4.3.2 High cost associated with PD-1 and PD-L1 inhibitors

4.3.3 Competition from alternative cancer treatment options

6.1 United States (US) PD-1 and PD-L1 Inhibitors Market, By Inhibitors

6.1.1 Overview and Analysis

6.1.2 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Inhibitors, 2021- 2031F

6.1.3 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By PD-1 Inhibitors, 2021- 2031F

6.1.4 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By PD-L1 Inhibitors, 2021- 2031F

6.2 United States (US) PD-1 and PD-L1 Inhibitors Market, By Application

6.2.1 Overview and Analysis

6.2.2 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Hodgkin Lymphoma, 2021- 2031F

6.2.3 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Kidney Cancer, 2021- 2031F

6.2.4 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Melanoma, 2021- 2031F

6.2.5 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Non-small Cell Lung Cancer, 2021- 2031F

6.2.6 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Other Applications, 2021- 2031F

6.3 United States (US) PD-1 and PD-L1 Inhibitors Market, By Distribution Channel

6.3.1 Overview and Analysis

6.3.2 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F

6.3.3 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F

6.3.4 United States (US) PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Online Pharmacies, 2021- 2031F

7.1 United States (US) PD-1 and PD-L1 Inhibitors Market Export to Major Countries

7.2 United States (US) PD-1 and PD-L1 Inhibitors Market Imports from Major Countries

8.1 Clinical trial success rate for PD-1 and PD-L1 inhibitors

8.2 Number of new drug approvals in the immunotherapy segment

8.3 Patient survival rates post-treatment with PD-1 and PD-L1 inhibitors

9.1 United States (US) PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Inhibitors, 2021 & 2031F

9.2 United States (US) PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Application, 2021 & 2031F

9.3 United States (US) PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F

10.1 United States (US) PD-1 and PD-L1 Inhibitors Market Revenue Share, By Companies, 2024

10.2 United States (US) PD-1 and PD-L1 Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters